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ABSTRACT
INTRODUCTION: This article explores variation in survival 
and mortality of Danish melanoma patients from 2012 to 
2017 in relation to their region of residence and 
socioeconomic status.
METHODS: Data were extracted from The Danish Melanoma 
Database, a clinical register, based on reports from hospital 
departments and dermatologists, and designed for quality 
improvement. The analysis included covariates at the person 
and tumour level. A cohort analysis was implemented to 
quantify the variations and identify the underlying 
mechanisms behind regional and socioeconomic variations 
in mortality of melanoma patients.
RESULTS: The mortality of melanoma patients varied 
between the five regions with mean hazard ratios (95% 
confidence interval) of 1.36 (1.07-1.74) in men and 1.44 (1.08-
1.92) in women between the regions with highest and lowest 
mortality. Mortality was highest in the patients with the 
lowest income and shortest education. Regional variation in 
mortality was attributable to underlying variation in tumour 
stage and thickness, and it was not confounded by other 
covariates.
CONCLUSIONS: The two regions with the lowest mortality 
(highest survival) had high absolute incidence rates of 
stage IA and thin melanomas, indicating a high level of 
diagnostic activity in these regions. There was no regional 
variation in the incidence of advanced melanoma. The 
optimal level of diagnostic investigation of skin lesions has 
yet to be established.
FUNDING: none.
TRIAL REGISTRATION: not relevant.
Regional and socioeconomic variation  
in survival of melanoma patients  
in Denmark
Marianne Steding-Jessen1, Henriette Engberg1-3, Inge Øster1, Jens Winther Jensen1, Lisbet Rosenkrantz Hölmich4-6 & Henrik Møller1
Melanoma is a malignant cancer that arises in the mel-
anocyte, a pigmented cell type that exists in many or-
gans and tissues, but most predominantly in the skin. 
International Classification of Diseases, tenth version 
(ICD-10) code C43 identifies melanoma of the skin, 
and this is the disease entity used in most epidemio-
logical melanoma research. 
Important adverse prognostic factors include male 
sex, larger Breslow thickness, ulceration of the tumour 
epithelium and a higher stage [1].
According to population-based cancer registration 
in Denmark [2], the annual incidence of melanoma of 
the skin in 2012-2016 was 900 in men and 1,042 in 
women. The disease can be progressive and fatal, but 
the annual numbers of deaths certified as caused by 
skin melanoma were much lower, 139 in men and 101 
in women. Incidence rates have increased in Europe in 
recent decades [3, 4], and survival has improved in the 
same period [5]. 
The risk of melanoma is related to sun exposure, 
 especially intermittent sunburn and exposure in child-
hood, but it is also related to other sources of ultra-
violet radiation such as the use of sun beds [6].
The primary treatment for melanoma of the skin is 
surgical excision of the tumour including a safety mar-
gin of surrounding tissue, and staging of the disease by 
excision of the directly draining lymph node(s) (senti-
nel node). For tumours included in this study, sentinel 
node biopsy was generally performed in tumours with 
a thickness of 1.0 mm or more, or if ulcerated or with 
dermal mitoses. Loco-regional metastases and distant 
oligo-metastatic disease may be treated surgically. 
Advanced cancer is treated with systemic immunother-
apy or targeted therapy. These modalities have shown 
remarkably good efficacy in advanced melanoma in re-
cent years, with prolonged survival an even occasion-
ally complete response, with patients potentially being 
cured [7]. 
The principal epidemiological analyses in this re-
port address the all-cause mortality of patients with 
melanoma of the skin in relation to their region of resi-
dence and their socioeconomic status. The five govern-
ment regions in Denmark are budget-holders and  
operationally responsible for the management and pro-
vision of healthcare services for their respective popula-
tions, and the comparison of the survival of their resi-
dent cancer patients is therefore relevant to the 
evaluation of their services and may serve to inform 
quality improvement initiatives.
METHODS
The present analyses used 13,817 cases of melanoma 
of the skin (C43) diagnosed in the period from 2012 to 
2017 in the RKKP clinical database for skin melanoma: 
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TABLE 1 / Cox regression analyses of all-cause mortality in relation to the available  variables on male and female melanoma patients, Denmark, 2012-2017a.
Men 
(n = 6,444)
Women 
(n = 7,373)
n Hr, mean (95% ci) p-value n Hr, mean (95% ci) p-value
Year of diagnosisb
2012
2013
2014
2015
2016
2017
1,011
   945
1,048
1,009
1,207
1,224
1.00 (ref.)
1.06 (0.87-1.29)
0.84 (0.68-1.04)
0.88 (0.70-1.10)
0.76 (0.60-0.97)
0.74 (0.55-1.01)
0.04
1,104
1,180
1,237
1,231
1,376
1,245
1.00 (ref.)
0.94 (0.74-1.20)
0.99 (0.77-1.28)
0.90 (0.68-1.19)
0.98 (0.73-1.31)
0.81 (0.54-1.23)
0.90
Age group, yrs
≤ 29
30-39
40-49
50-59
60-69
70-79
≥ 80
  195
   391
   802
1,037
1,605
1,672
   742
0.08 (0.01-0.60)
0.33 (0.15-0.71)
0.40 (0.24-0.67)
0.62 (0.42-0.92)
1.00 (ref.)
2.11 (1.63-2.74)
6.91 (5.37-8.87)
< 0.0001
  470
   761
1,374
1,287
1,450
1,206
   825
0.14 (0.05-0.45)
0.18 (0.08-0.42)
0.31 (0.18-0.54)
0.53 (0.33-0.85)
1.00 (ref.)
1.81 (1.29-2.54)
6.35 (4.72-8.55)
< 0.0001
Charlson Comorbidity Index
0
1-2
≥ 3
4,506
1,307
   631
1.00 (ref.)
1.44 (1.23-1.69)
2.47 (2.08-2.94)
< 0.0001
5,682
1,271
   420
1.00 (ref.)
1.66 (1.37-2.01)
3.09 (2.48-3.86)
< 0.0001
Region of residence
North Denmark Region
Central Denmark Region
Region of Southern Denmark
Region Zealand
Capital Region of Denmark
  553
1,099
1,528
   930
2,334
1.36 (1.07-1.74)
1.23 (1.02-1.49)
1.07 (0.90-1.29)
1.27 (1.04-1.56)
1.00 (ref.)
0.03
  637
1,325
1,846
1,025
2,540
1.44 (1.08-1.92)
1.15 (0.92-1.45)
1.05 (0.85-1.31)
1.26 (0.98-1.62)
1.00 (ref.)
0.09
Civil status
Married
Cohabiting
Single
4,426
1,262
   756
1.00 (ref.)
1.53 (1.32-1.79)
1.20 (0.88-1.63)
< 0.0001
3,995
2,130
1,248
1.00 (ref.)
1.17 (0.96-1.43)
1.70 (1.20-2.42)
0.008
Education
School
Professional education
Shorter further education
Longer further education
Unknown
1,317
2,946
1,316
   747
   118
1.00 (ref.)
0.85 (0.72-0.99)
0.64 (0.51-0.79)
0.68 (0.51-0.89)
0.86 (0.60-1.23)
< 0.0004
1,734
2,952
1,985
   587
   115
1.00 (ref.)
0.85 (0.70-1.02)
0.70 (0.54-0.90)
0.78 (0.46-1.30)
0.88 (0.61-1.29)
0.08
Income
Quartile 1
Quartile 2
Quartile 3
Quartile 4
1,611
1,611
1,611
1,611
1.00 (ref.)
0.93 (0.80-1.09)
0.73 (0.60-0.90)
0.60 (0.47-0.76) 
< 0.0001
1,844
1,843
1,843
1,843
1.00 (ref.)
1.01 (0.84-1.21)
0.80 (0.61-1.05)
0.77 (0.58-1.02)
0.12
Tumour stage
IA
IB
IIA
IIB
IIC
III
IV
Unknown
3,001
1,286
   482
   307
   198
   678
     93
   399
1.00 (ref.)
1.47 (1.17-1.85)
2.21 (1.70-2.87)
3.16 (2.45-4.08)
5.27 (4.09-6.78)
4.47 (3.63-5.52)
17.00 (12.71-22.74)
2.13 (1.62-2.80)
< 0.0001
3,870
1,556
   513
   265
   164
   507
     47
   451
1.00 (ref.)
1.20 (0.89-1.60)
2.29 (1.71-3.08)
4.28 (3.23-5.68)
5.73 (4.27-7.69)
5.81 (4.47-7.55)
17.00 (11.14-25.97)
1.59 (1.11-2.26)
< 0.0001
Breslow thickness, mm
0-1
1-2
> 2
Unknown
3,622
1,200
1,226
   396
1.00 (ref.)
1.72 (1.41-2.12)
3.85 (3.28-4.52)
1.96 (1.51-2.53)
< 0.0001
4,590
1,354
   968
   461
1.00 (ref.)
1.47 (1.14-1.90)
4.13 (3.39-5.03)
1.85 (1.36-2.52)
< 0.0001
CI = confidence interval; HR = hazard ratio; ref. = reference.
a) Supplementary material gives more detailed tabulations of covariates in the five regions, contact the correspondence author.
b) p < 0.0001. CONTINUES 
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The Danish Melanoma Database [8]. The data are 
based on reports from hospital departments and prac-
ticing dermatologists and were validated against the 
 Danish Pathology Register.
Data on household income, education, civil status, 
and comorbidity were obtained by linkage to Statistics 
Denmark, the Central Person Register and the National 
Hospital Discharge Register, respectively [9-11]. 
Household income per person in the year before 
cancer diagnosis was analysed by quartiles of the in-
come distribution for melanoma patients, separately 
for men and women. The highest attained education 
for each person was classified as either basic school 
 education (the compulsory school education only); 
professional education (including for example appren-
ticeships and including high-school only); shorter 
 further education; and longer further education. Civil 
status was classified as married or in registered part-
nership; other cohabiting persons; single. Comorbidity 
was characterised by the Charlson Index, computed on 
the basis of hospital discharge diagnoses in the ten-year 
period leading up to the cancer diagnosis. Missing 
 values were analysed as a separate category.
A cohort analysis was conducted of the occurrence 
of deaths in relation to time at risk from date of diagno-
sis until death, emigration or end-of-follow-up on 8 
October 2018, whichever occurred first. This was im-
plemented as a Cox regression model using time since 
date of diagnosis as the principal time dimension. 
Analyses were conducted for men and women separ-
ately, and the basic models included age (continuous 
quadratic function to account for the non-linear associ-
ation between age and mortality), sex and year of diag-
nosis (categorical) as covariates. Further covariates 
were added separately to the basic model to identify 
confounding or mediating characteristics. 
Trial registration: not relevant.
RESULTS
Table 1 shows the distributions of covariates among 
male and female patients. The overall distributions of 
age, comorbidity, stage, Breslow thickness, anatomic 
localisation and histology were as one would expect in 
a population-based cohort of melanoma patients.
Incidence rates of melanoma differed between re-
gions. The highest incidence for both sexes occurring in 
The Capital Region and The Region of Southern Den-
mark, and the lowest in the North Denmark Region and 
in The Central Denmark Region. Mortality rates were 
more similar in the regions, but lowest in The Capital 
Region, especially in women. In both sexes, The Capital 
Region had the highest proportions of younger pa-
tients, patients with stage IA melanoma, patients with 
thin lesions and patients with superficially spreading 
melanoma.
Figure 1 shows the Kaplan-Meier survival functions 
for all-cause mortality of male and female melanoma 
patients. Regional variation in survival emerged gradu-
ally over the six-year follow-up period. Log-rank tests 
were p = 0.04 and p = 0.07 for men and women, re-
spectively. Survival was highest among the patients of 
The Capital Region and The Region of Southern 
Denmark, lower in The Central Denmark Region and 
The Zealand Region, and lowest in the North Denmark 
Region.
Table 1 presents the results from regression analy-
ses, with each variable analysed separately, but ad-
TABLE 1 CONTINUED / Cox regression analyses of all-cause mortality in relation to the available  variables on male and female melanoma patients, 
Denmark, 2012-2017a.
Men 
(n = 6,444)
Women 
(n = 7,373)
n Hr, mean (95% ci) p-value n Hr, mean (95% ci) p-value
Anatomic site
Head and neck
Back
Front
Extremities
Genitals or unknown
1,080
2,558
1,047
1,606
   153
1.17 (0.96-1.48)
1.16 (0.97-1.40)
1.08 (0.86-1.37)
1.00 (ref.)
1.83 (1.31-2.55)
< 0.0001
  764
1,817
   689
3,915
   188
1.21 (0.97-1.50)
1.21 (0.98-1.51)
1.22 (0.86-1.73)
1.00 (ref.)
1.74 (1.21-2.50)
0.02
Morphology
Lentigo malignant melanoma
Nodular melanoma
Superficially spreading melanoma
Other or unknown
   279
   611
4,964
   590
1.00 (ref.)
2.56 (2.16-3.05)
1.13 (0.86-1.48)
1.71 (1.41-2.08)
< 0.0001
  265
   571
5,863
   674
1.00 (ref.)
2.42 (1.96-2.98)
0.89 (0.64-1.23)
1.90 (1.51-2.39)
< 0.0001
CI = confidence interval; HR = hazard ratio; ref. = reference.
a) Supplementary material gives more detailed tabulations of covariates in the five regions, contact the correspondence author.
b) p < 0.0001.
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justed for year of diagnosis, age and comorbidity. 
Mortality rates were highest in older persons and per-
sons with comorbidity, advanced stage, thick mela-
noma, nodular melanoma or localisation on the head 
or trunk (and lowest when on the extremities). Mor-
tality decreased with calendar time of diagnosis, but 
this trend was only statistically significant in men. 
Mortality was lowest in persons with a high education 
or a high income. This trend was statistically significant 
in men. Married persons had a lower mortality than co-
habiting and single persons. Comparison of the regions 
showed small differences in the mortality of melanoma 
patients, but consistent with the Kaplan-Meier esti-
mates with the highest mortality in men and women  
in The North Denmark Region, intermediate in the 
Cen tral Denmark Region and in Region Zealand, and 
lowest in The Region of Southern Denmark and The 
Capital Region. 
Table 2 provides more detail on the variation in 
mortality between patients in the five regions. The ex-
cess mortality rates in patients in The North Denmark 
Region and the Central Denmark Region were much 
 attenuated when estimates were adjusted for tumour 
stage or for Breslow thickness. The excess mortality in 
men and women in Region Zealand was mostly ob-
served in men, but it was not very strong, and it was at-
tributable to stage and thickness. However, for women, 
the excess mortality was more strongly attributable to 
these two variables. In fully adjusted regression mod-
els, the variation between patients residing in different 
regions was much reduced, and the variables that ex-
plain this reduction were tumour thickness and stage.
Unlike the variation between regions, the magni-
tude of the variation between income groups was not 
sensitive to adjustment for available covariates (data 
not shown).
DISCUSSION
The variation in mortality of melanoma patients 
 between Danish regions was most strongly associated 
with variation in tumour stage and thickness; and the 
favourable case-mix in the Capital Region and Region 
of  Southern Denmark was possibly owed to more in -
tensive diagnostic investigation in these regions. The 
 Capital Region, especially, has more practicing derma-
tologists than the remaining regions [12]. 
The results are consistent with a scenario in which 
increased diagnostic intensity enriches the patient 
popu lation with thin melanoma and stage IA mela-
noma, including a subgroup of cancers that are slow-
growing, and probably would not be diagnosed in the 
lifetime of the person if the diagnostic intensity had 
been lower [13]. This leads to a pattern of increased 
population incidence, more favourable case-mix, and a 
lower patient mortality, but no reduction in the popula-
tion rate of  occurrence of fatal melanomas and no re-
duction in the population mortality rate. A study from 
the US analysed skin biopsy rates and melanoma inci-
dence and mortality in nine geographical areas [14].  
A strong  association was found between biopsy rates 
and incidence rates. The excess rate attributable to bi-
opsy rates was confined to early-stage cancers, and 
there was no association with advanced melanomas or 
with melanoma mortality.
FIGURE 1 / Kaplan-Meier survival functions for death from any cause among male (A) and female (B) melanoma patients in 
 Denmark, 2012-2017.
Survival, % Survival, %
Region of residence
 North Denmark Region     Central Denmark Region     Region of Southern Denmark      Region Zealand     Capital Region of Denmark
7 76 65 54 40 01 12 23 3
Time after diagnosis, yrs Time after diagnosis, yrs
70 70
75 75
80 80
85 85
90 90
95 95
100 100
A B
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The country with the historically highest melanoma 
incidence rate in the world is Australia [15]. This is 
mainly attributable to extreme sunlight exposure in the 
susceptible Caucasian population [16]. Australia had 
incidence rates of 40.4 per 100,000 in males and 28.6 
per 100,000 in females in 2008-2012 [15]. It is remark-
able that in the same period (2008-2012), Danish 
women in the Capital Region and the Region of 
Southern Denmark had similar or higher incidence 
rates than women in Australia (the Capital Region 
34.4; the Region of Southern Denmark 28.3 [2] versus 
Australia 28.6 [15]). Apart from differences in diagnos-
tic activity, comparison between countries may be com-
plicated by different patterns of exposure, e.g. ambient 
sunlight, sun-seeking behaviour and summer holidays, 
and use of sun beds which may vary between countries 
[6, 16].
We found a strong association between personal 
 income and mortality for male patients, but a weaker 
association for women. The association was not sensi-
tive to adjustment for person- and tumour characteris-
tics. We cannot exclude that the association in men 
may be dominated by the general difference in life ex-
pectancy between socioeconomic groups rather than by 
a differential mortality from the melanoma. This might 
be  improved by considering melanoma-specific mortal-
ity  instead of all-cause mortality.
In a recent Danish study, an increased risk of being 
diagnosed with melanoma at a more advanced stage 
was found among patients with lower education and 
lower income [17]. These findings are based on com-
bined analysis of men and women and are consistent 
with the present study results.
Figure 2 presents the age-standardised rates of 
 categories of stage and Breslow thickness in Denmark‘s 
five regions. The lasting impression is that the variable 
rates of stage IA cancers and thin melanoma explain 
the overall difference in incidence between the regions, 
whereas the rates of advanced cancers and thick mela-
noma are constant.  
Although these results are indicative of a high inten-
sity of diagnostic intervention in the Capital Region 
and the Southern Denmark Region, and suggestive of a 
possible over-diagnosis scenario, the importance of 
early detection must be emphasised. Data from Aus-
tralia show that about 24% of melanoma deaths were 
preceded by diagnosis of melanoma with a Breslow 
thickness of 1 mm or less [18]. It cannot be assumed 
that stage IA and thin melanoma are harmless. A recent 
analysis from Sydney, Australia of more than 6,000 
TABLE 2 / Cox regression analyses of all-cause mortality in relation to region of residence of male and female melanoma patients, Denmark, 2012-2017. 
 Sensitivity analyses for available covariates. The values are mean hazard ratio (95% confidence interval)a.
Model 1b
(p = 0.03/0.09)c
Model 1b  
+ civil status
(p = 0.02/0.06)c
Model 1b  
+ education
(p = 0.06/0.12)c
Model 1b  
+ income
(p = 0.06/0.14)c
Model 1b  
+ tumour stage
(p = 0.17/0.92)c
Model 1b  
+ Breslow 
 thickness
(p = 0.47/0.51)c
Model 1b  
+ anatomic site
(p = 0.02/0.06)c
Model 1b  
+ morphology
(p = 0.08/0.10)c
all covariates
(p = 0.58/0.83)c
Males
North  
Denmark  Region
Central  
Denmark Region
Region of  
Southern Denmark
Region Zealand
Capital Region  
of Denmark
1.36 (1.07-1.74)
1.23 (1.02-1.49)
1.07 (0.90-1.29)
1.27 (1.04-1.56)
1.00 (ref.)
1.37 (1.07-1.74)
1.24 (1.02-1.50)
1.10 (0.92-1.31)
1.29 (1.06-1.59)
1.00 (ref.)
1.31 (1.02-1.67)
1.20 (0.99-1.46)
1.03 (0.86-1.23)
1.24 (1.01-1.52)
1.00 (ref.)
1.29 (1.01-1.65)
1.19 (0.98-1.44)
1.00 (0.83-1.20)
1.22 (0.99-1.50)
1.00 (ref.)
1.22 (0.96-1.56)
0.96 (0.79-1.17)
1.07 (0.89-1.29)
1.21 (0.98-1.48)
1.00 (ref.)
1.14 (0.90-1.46)
1.08 (0.89-1.31)
1.02 (0.85-1.23)
1.19 (0.97-1.46)
1.00 (ref.)
1.36 (1.07-1.74)
1.22 (1.01-1.48)
1.02 (0.85-1.23)
1.26 (1.03-1.55)
1.00 (ref.)
1.28 (1.01-1.64)
1.13 (0.93-1.37)
1.03 (0.85-1.23)
1.26 (1.03-1.55)
1.00 (ref.)
1.09 (0.85-1.40)
0.99 (0.81-1.21)
0.99 (0.82-1.20)
1.15 (0.94-1.42)
1.00 (ref.)
Females
North  
Denmark  Region
Central  
Denmark Region
Region of  
Southern Denmark
Region Zealand
Capital Region  
of Denmark
1.44 (1.08-1.92)
1.15 (0.92-1.45)
1.05 (0.85-1.31)
1.26 (0.98-1.62)
1.00 (ref.)
1.46 (1.09-1.94)
1.17 (0.93-1.47)
1.06 (0.85-1.32)
1.28 (1.00-1.65)
1.00 (ref.)
1.40 (1.05-1.86)
1.13 (0.90-1.42)
1.00 (0.80-1.25)
1.22 (0.94-1.57)
1.00 (ref.)
1.39 (1.04-1.86)
1.14 (0.90-1.43)
1.02 (0.81-1.27)
1.22 (0.94-1.57)
1.00 (ref.)
1.11 (0.83-1.48)
1.06 (0.84-1.34)
1.08 (0.87-1.35)
0.99 (0.77-1.28)
1.00 (ref.)
1.24 (0.93-1.66)
1.13 (0.90-1.42)
1.02 (0.82-1.27)
1.15 (0.90-1.49)
1.00 (ref.)
1.44 (1.08-1.91)
1.18 (0.94-1.49)
1.01 (0.81-1.26)
1.26 (0.98-1.62)
1.00 (ref.)
1.40 (1.05-1.87)
1.16 (0.92-1.46)
1.05 (0.84-1.31)
1.28 (0.99-1.65)
1.00 (ref.)
1.11 (0.82-1.49)
1.12 (0.88-1.42)
1.05 (0.83-1.33)
0.97 (0.74-1.26)
1.00 (ref.)
ref. = reference.
a) Supplementary material gives more detailed tabulations of covariates in the five regions, contact the correspondence author.
b) Model 1 includes age, year of diagnosis and Charlson Comorbidity Index.
c) Males/females.
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melanoma patients showed that melanoma with a 
thickness of 0.8-1.0 mm carried a higher long-term 
mortality than thinner melanoma [19]. This signals the 
need to develop prognostic markers of long-term out-
comes in stage I and thin melanoma. 
The present analysis does not include details on the 
surgical and other oncological treatment of each pa-
tient, and these data do not rule out a role of treatment 
variation in the observed variation in mortality. The 
 initial treatment is likely to be similar in the regions, 
with surgical excision being the primary treatment of 
almost all patients.
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FIGURE 2 / Stacked bar charts of age-standardised incidence rates per 100,000 of tumour stage IA, IB, and II, III, IV, (A men,  
B women) and of categories of Breslow thickness (C men, D women) in Danish regions, 2012-2017.
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